Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of fludarabine + treosulfan conditioning before allogeneic stem cell transplantation in acute myeloid leukemia
2021-006515-28Phase 2Active
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine and treosulfan in acute myeloid leukemia (AML), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: 1-year leukemia-free survival. Started Jan 2022; status: active.
02
Drugs
fludarabinetreosulfan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-006515-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006515-28.